Socioeconomic analysis of CSE-inhibition in patients with CAD;Die wirtschaftlichkeit von arzneimitteltherapien am beispiel von pravastatin

Medizinische Klinik

Volumn 92, Issue 6, 1997, Pages 363-369

  Berger, Karin ^a   Klose, Gerald ^d   Szucs, Thomas D ^a,b,c  

^a Forschungsgruppe Medizin Okonomie   (Germany)

^b School of Pharmacy   (Italy)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Zentralkrankenhaus Links der Weser   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN;

ANALYTIC METHOD; ARTICLE; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ENZYME INHIBITION; HUMAN; LIFE EXPECTANCY; META ANALYSIS; SOCIOECONOMICS;

EID: 0030740632     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044779     Document Type: Article

References (29)

1. Ashraf, T., J. Hay, Pitt et al.: Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Eingereicht in Amer. J. Cardiol.
2. Bundesverband der Pharmazeutischen Industrie e, V. (Hrsg.): Role Liste 1996. Edito-Cantor, Aulendorf 1995.
3. Byington, R. P., J. W. Jukema et al.: Reduction in cardiovascular events during pravastatin therapy. Circulation 92 (1995), 2419-2425.
4. Crouse, J. R. 3rd, R. P. Byington, M. G. Bond, M. A. Espeland, T. E. Craven, J. W. Sprinkle, M. E McGovern, C. D. Furberg Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Amer. J. Cardiol. 75 (1995), 455-459.
5. Drummond, M. F., G L. Stoddart, G. W. Torrance: Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford 1986.
6. Goldman, L., S. T. B. Sia, E. F. Cook, J. D. Rutherford, M. C. Weinstein: Costs & effectiveness of routine therapy with long-term beta-adreneric antagonists after acute myocardial infarction. New Engl. J. Med. 319 (1988), 152-157.
7. Hillner, B. E., T. J. Smith: Efficacy & cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. New Engl. J. Med. 324 (1991), 160-168.
8. 8; Jönsson, B., M. Johannesson, J. Kjeksjus et al.: Cost-effectiveness of cholesterol lowering. Europ. Heart J. 17 (1996), 1001-1007.
9. Johannesson, M., B. Jönsson, J. Kjekshus et al.: Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. New Eng|. J. Med. (1997), 332-336.
10. Kempel, A., et al.: Kosten-Nutzen-Analyse zeigc ökonomische Vorteile auf. Beilage in: Internist (Berl.) 35 (1994), 6.
11. Laupacis, A., et al.: How attractive does a new technology have to be to warrant adaption? Canad. med. Ass. J. 146 (1992), 473-481.
12. Mark, D. B., M. A. Hlatky, R. M. Califf et al.: Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New Engl. J. Med. 332 (1995), 1418-1431.
13. Oberender, P.: Pharmakoökonomie: Notwendigkeit, Möglichkeiten und Grenzen pharmaökonomischer Studien. In: Oberender, P. (Hrsg.): Kosten-Nutzen-Analysen in der Pharmaökonomie. SMVerlagsgesellschaft mbH, Gräfelfing 1995, S. 22.
14. Owens, D. K., A, Harris, P, Scott et al.: Screening surgeons for HIV infection. Ann. intern. Med. 122 (1995), 641-652.
15. Pitt, B., S. G. Ellis, G. B. Mancini, H. S. Rosman, M. E. McGovern: Design and recruitment in the United States of a multiplecenter quantitative angiographic trial of pravastatin to limit atherosclerosis in coronary arteries (Plac-I). Amer. J. Cardiol. 72 (1993), 31-35.
16. Pitt, B., C. Furberg et al. for the Plac I and Plac II investigators: Reduction in cardiovascular events during treatment with pravastatin: pooled analysis from coronary and carotid atherosclerosis intervention trials. Europ. Heart J. 15, Suppl. (1994), 2565.
17. Ruckdäschel, K. Berger, Th. Szucs: Koronare Herzkrankheit ein sozioökonomisches Problem? Münch. med. Wschr. 138 (1996), 404-408.
18. Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen: Gesundheitsversorgung und Krankenversicherung 2000, 1. Auflage. Nomos, Baden-Baden 1994, S. 49-72.
19. Sacks, F. M., M. D. Pfeffer et al. for the cholesterol and recurrent events trial investigators (CARE): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335 (1996), 1001-1009.
20. Scandinavian Simvastatin Survival Study Group (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383-1389.
21. SGB V Gesetzliche Krankenversicherung, 3. Auflage., Beck-Texte 5559, 1993.
22. Shepherd, J., S. M. Cobbe et al. for the West of Scotland Coronary Prevention Study Group (WOS): Prevention of coronary heart disease with pravastatin in men with Hypercholesterolemia. New Engl. J. Med. 333 (1995), 1301-1307
23. Stason, W. B., M. C. Weinstein: Allocation of resources to manage hypertension. New Engl. J. Med. 296 (1977), 732-739.
24. Statistisches Bundesamt (Hrsg.): Statistisches Jahrbuch für die Bundesrepublik Deutschland 1994. Metzler-Poeschel, Wiesbaden 1994, S. 447-478.
25. Szucs, T., K. Berger, J. Schulte-Hillen, F. X. Kleber: Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klin. 91 (1996), 112-118.
26. Tengs, T. O., M. E. Adams, J. S. Pliskin et al.: Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 15 (1995).
27. Taylor, W. C., T. M. Pass, D. S. Shepard, A. L. Komaroff: Cost-effectiveness of cholesterol reduction for the primary prevention of coronay heart disease in men. Preventing disease: Beyond the rhetoric. Springer, Berlin - Heidelberg-New York 1990.
28. Tunstall, P. H., A. Kuulasmaa, P. Amouyel, D. Arveiler, A. M. Rajakangas, A. Pajak: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994), 583-612.
29. Weinstein, C. M., B William, B. Stason. Foundations of cost-effectiveness analysis for health and medical practices. New Engl. J. Med. 31 (1977), 716-721.